Literature DB >> 10848653

Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.

P O Katz1, J G Hatlebakk, D O Castell.   

Abstract

BACKGROUND: In patients with severe gastro-oesophageal reflux disease (GERD), proton pump inhibitors are being used increasingly in twice-daily regimens to improve control of gastric acidity. Few data exist to compare the ability of the most-often used proton pump inhibitors, omeprazole and lansoprazole, to control gastric acid at twice-daily dosage regimens. Nocturnal acid breakthrough, defined as gastric pH < 4.0 continuously for > 60 min, may compromise treatment goals in patients with GERD. AIM: To compare the effects of omeprazole 20 mg b.d. or lansoprazole 30 mg b.d. on gastric acidity and the relative ability of each dosage regimen to prevent acid breakthrough.
METHODS: In a crossover pharmacodynamic study, 20 healthy volunteers (10 male, 10 female, mean age 38 years) were given omeprazole 20 mg b.d. or lansoprazole 30 mg b.d. for 7 days each, in a randomized manner. Each dosage regimen was separated by a minimum 7-day period where no medication was administered. On day 7 of each regimen, 24-h intragastric pH-metry was performed. The percentage of time for which gastric pH was below 4.0 and 3.0, the occurrence of daytime and nocturnal acid breakthrough, and the duration of action of each regimen were compared. Non-parametric statistics for paired data were used.
RESULTS: The percentage time for which gastric pH was below 4.0 was significantly lower with omeprazole 20 mg b.d. (median 14.8%) than with lansoprazole 30 mg b. d. (median 24.2; P=0.0372). Fourteen subjects showed more effective acid control when taking omeprazole; these were significantly more often H. pylori-negative patients compared with those for whom acid control was better on lansoprazole (P < 0.001). Nocturnal acid breakthrough occurred in seven patients (35%) on omeprazole and in 10 (50%) on lansoprazole (N.S.).
CONCLUSION: In healthy volunteers, twice-daily dosing of omeprazole 20 mg b.d. appears to be significantly more effective than lansoprazole 30 mg b.d. in controlling gastric acidity. The clinical importance of such a difference remains to be defined in GERD patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848653     DOI: 10.1046/j.1365-2036.2000.00775.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

Review 1.  Gastroesophageal reflux disease and sleep disturbances.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa; Ronnie Fass
Journal:  J Gastroenterol       Date:  2012-05-17       Impact factor: 7.527

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.

Authors:  Eunwoo Kim; Anhye Kim; Sojeong Yi; Yu Kyong Kim; Seong Bok Jang; Hae Mi Byun; Seo Hyun Yoon; Joo-Youn Cho; In-Jin Jang; Kyung-Sang Yu; SeungHwan Lee
Journal:  Eur J Clin Pharmacol       Date:  2018-06-15       Impact factor: 2.953

Review 5.  Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.

Authors:  J Enrique Domínguez-Muñoz; Miguel Sobrino
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.

Authors:  Jun Matsukawa; Akifumi Kogame; Yoshihiko Tagawa; Nobuhiro Inatomi
Journal:  Dig Dis Sci       Date:  2016-03-09       Impact factor: 3.199

7.  High-output fistula.

Authors:  Naila Arebi; Alastair Forbes
Journal:  Clin Colon Rectal Surg       Date:  2004-05

Review 8.  The pharmacology and clinical relevance of proton pump inhibitors.

Authors:  Philip O Katz; Christine Frissora
Journal:  Curr Gastroenterol Rep       Date:  2002-12

Review 9.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 10.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.